Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.87 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.87 |
| ▸ | MLNR | O43193 | 1/20 | 0.87 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | HTR1A | P08908 | 1/20 | 0.87 |
| ▸ | GAA | P10253 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | DRD2 | P14416 | 1/20 | 0.87 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.87 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | HTR2C | P28335 | 1/20 | 0.87 |
| ▸ | MC4R | P32245 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL2120068 | 0.96 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29389952 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30523711 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL120750 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL119403 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3896385 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3335 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182156-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| EP-1971592-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | Medichem, S.A. (ES) | 2008-09-24 | — | — | EP | claimed |
| WO-2007119114-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | claimed |
| CN-113603673-A | Duloxetine hydrochloride crystal form, preparation method and application thereof | 上海中西三维药业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-103626735-A | Duloxetine hydrochloride crystal form and preparation method thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2014-03-12 | — | — | CN | disclosed |
| US-8158808-B2 | Synthesis and preparations of duloxetine salts | MEDICHEM S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| US-20100286412-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | WINTER STEPHEN BENEDICT DAVID | 2010-11-11 | — | — | US | disclosed |
| US-20090182156-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (ES) | 2009-07-16 | — | — | US | disclosed |
| US-20090093645-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (ES) | 2009-04-09 | — | — | US | disclosed |
| EP-1971592-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | Medichem, S.A. (ES) | 2008-09-24 | — | — | EP | disclosed |
| EP-1971591-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | Medichem, S.A. (ES) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007119114-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007096707-A2 | IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286412-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | CYP2D6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 11/4885 |
| US-20090182156-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20090093645-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | SLC6A2, SLC6A4, CYP2D6 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.